Use in the United States began on June 18, with no safety signals identified as of July 27.
Moderna vaccine for children 6 months to 5 years was approved by Health Canada on July 14, 2022. Parents of children 6 months to 4 years of age who live in First Nations communities can call the health centre in their community to book an appointment. Children 6 months to 4 years (booking opens August 2) Minors under 18 require verbal or written consent from a parent or guardian to be vaccinated. When to book: Must wait at least 5 months after fourth dose. 
Eligibility: Albertans 18 and older with eligible immunocompromising conditions.
When to book: Must wait at least 5 months after third dose.įifth dose (second booster) for immunocompromised 18+ (starting July 20). Eligibility: Albertans 12 and older with eligible immunocompromising conditions. How to book: Call 811 or book online (pharmacy or AHS clinic).įourth dose (first booster) for immunocompromised 12+. When to book: Recommended to wait 28 days between the first and second dose, and 8 weeks between the second and third dose. Eligibility: Albertans 5 and older with eligible immunocompromising conditions. Three-dose primary series for immunocompromised 5+ Individuals taking certain medications for autoimmune diseases including rituximab, ocrelizumab, ofatumumab and methotrexate. 
Recipients of active cancer treatment (chemotherapy, immunotherapy or targeted therapies), excluding those receiving only hormonal therapy, radiation therapy or surgery. Individuals with chronic kidney disease receiving regular dialysis. Transplant recipients, including solid organ and hematopoietic stem cell transplants. Recipients of immunosuppressive therapies (for example, anti-B cell therapies, high-dose systemic corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents). Individuals with advanced untreated HIV infection or acquired immunodeficiency syndrome (AIDS). Individuals with moderate to severe primary immunodeficiency (for example, DiGeorge syndrome, Wiskott-Aldrich syndrome). Recipients of chimeric antigen receptor (CAR)-T-cell therapy. Individuals with certain immunocompromising conditions should receive a 3-dose primary series, followed by all of the booster doses they are eligible for. This is to provide stronger protection because their immune systems respond differently to vaccines than other people without these conditions.
0 kommentar(er)
